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Abstract: Vascular smooth muscle cells (VSMCs) loaded with lipid droplets (LDs) are markers of
atherosclerosis. In this disease, inflammatory Group IIA-secreted phospholipase A2s (GIIA sPLA2s)
are highly expressed in VSMCs, but their actions in these cells are unknown. Here, we investigated
the ability of myotoxin III (MT-III), an ophidian GIIA sPLA2 sharing structural and functional features
with mammalian GIIA sPLA2s, to induce LD formation and lipid metabolism factors involved in this
effect. Modulation of VSMC phenotypes by this sPLA2 was also evaluated. Incubation of VSMCs
with MT-III significantly increased the number of LDs. MT-III upregulated scavenger receptor type
1 (SR-A1) and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) protein expression
and enhanced acetylated-low density lipoprotein (acLDL) uptake by VSMCs, revealing the ability of
a GIIA PLA2 to modulate scavenger receptor activities. MT-III induced translocation and protein
expression of PPAR-γ and -β/δ. Inhibition of peroxisome proliferator-activated receptors (PPARs) and
diacylglycerol O-acyltransferase (DGAT) and acyl-CoA:cholesterolacyltransferase (ACAT) enzymes
abrogated MT-III-induced LD formation. Moreover, in response to MT-III, VSMCs acquired phagocytic
activity and expressed macrophage markers CD68 and MAC-2. In conclusion, MT-III is able to
stimulate VSMCs and recruit factors involved in lipid uptake and metabolism, leading to the formation
of VSMC-derived foam cells with acquisition of macrophage-like markers and functions.
Keywords: phospholipase A2; vascular smooth muscle cells; lipid droplets
1. Introduction
Vascular smooth muscle cells (VSMC) are the main stromal cells of the vascular wall and play
essential roles in the regulation of blood vessel tone and blood flow [1]. Under inflammatory processes,
such as atherosclerosis, in addition to the differentiation from quiescent contractile to proliferative
synthetic phenotypes [2], which actively contributes to formation of atheromatous plaque, VSMCs
undergo phenotypic modification that is characterized by the expression of macrophage markers and
assume macrophage functions [3,4]. In addition, the differentiated VSMCs express a variety of fatty
acids and cholesterol uptake receptors [5], favoring the capture of fatty acids and cholesterol, giving
rise to a significant number of VSMC-derived foam cells characterized by a cytoplasm packed with
lipid droplets (LDs). These cytoplasmic organelles are well-known to be found in increased numbers
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in cells associated with inflammatory processes, such as macrophages [6,7]. Among the proteins
compartmentalized by LDs are those from the perilipin family (PLIN). These proteins are recruited to
the ER during LD biogenesis, favoring fatty acids capture [8] and regulating LD formation [9]. LDs are
composed mainly of triacylglycerol and cholesterol. The production of these neutral lipids is regulated
by the enzymes diacylglycerol O-acyltransferase (DGAT) and acyl-CoA:cholesterolacyltransferase
(ACAT), which esterify triacylglycerol and cholesterol, respectively, leading to the storage of these
neutral lipids in LDs [10,11]. In addition, the transcription factors peroxisome proliferator-activated
receptors (PPARs) orchestrate LD biogenesis through free fatty acid uptake by increasing the expression
of scavenger receptors and proteins related to lipid metabolism [12].
Secreted PLA2s (sPLA2s) are recognized as key regulators of LD formation by providing free fatty
acids from membrane phospholipids that are essential for this process, thus directly regulating the
assembly of these organelles [13]. This superfamily of enzymes comprises several groups, including
those of group IIA (GIIA), which have been reported to be expressed in high levels in vessel wall cells,
such as VSMCs, in macrophage-rich regions, and in the extracellular matrices of the affected intima
during the atherosclerotic process [14]. Presently, the participation of GIIA sPLA2s in the development
of atherosclerosis is associated with their ability to modify low-density lipoprotein (LDL) particles,
generating more proaterogenic particles and the production of inflammatory lipid mediators [15].
However, the potential role of this group of enzymes in the formation of VSMC-derived foam cells
needs to be addressed.
Snake venom group IIA sPLA2s share structural and functional features with mammalian
inflammatory group IIA sPLA2s [16]. Similar to mammalian sPLA2s, the venom sPLA2s, such as MT-III,
which has been isolated from Bothrops asper snake venom, exhibit the ability to induce inflammatory
events in both in vivo and in vitro experimental models [17–19]. Considering the contribution of
sPLA2s to lipid accumulation and the formation of LDs in macrophages, the question arises of the
effect MT-III has on VSMC regarding the formation of LD formation, considering related mechanisms
and the phenotypical identity of VSMCs.
2. Results
2.1. LD Formation Induced by MT-III in Vascular Smooth Muscle Cells
To access the capability of a GIIA sPLA2 MT-III to induce LD formation in VSMC, cells were
incubated with selected concentrations of MT-III. Preliminary assays were performed using VSMCs
freshly isolated from rat aorta (passage zero) to evaluate the influence of differentiation state of cells
and cell phenotypes on lipid droplets formation induced by MT-III. The incubation of MT-III (0.4 and
0.8 µM) for 3, 6, and 12 h did not increase lipid droplet formation in comparison with non-stimulated
control cells (data not shown). Therefore, in the present study, modulation and de-differentiation of
VSMCs was induced by serum before the addition of MT-III and all assays were performed using
the 5th to 8th passage cells. In this experimental condition VSMCs are responsive to MT-III stimulus,
producing lipid droplets. As demonstrated in Figure 1a,b, incubation of VSMC with MT-III induced a
significant increase of LDs in a time- and concentration-dependent manner. MT-III incubated for 1 h at
concentrations from 0.4 to 0.8 µM induced a significant increase in the number of LDs in comparison
with control cells incubated with culture medium alone. This effect was detected up to 12 h (Figure 1b).
As illustrated in Figure 1c, control VSMCs stained with OsO4 showed no LDs in the cytoplasm.
In contrast, MT-III-stimulated VSMCs exhibited a cytoplasm packed with the osmiophilic organelles,
which can be seen as dark punctate structures. These data indicate that MT-III induces LD formation
in VSMC in a time- and dose-dependent manner.
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Figure 1. MT-III induces LD formation in VSMCs. (A) Effect of MT-III on LD formation in VSMCs 
stimulated with selected concentrations of MT-III or with DMEM (control) for 1 h. (B) Time-course 
of MT-III-induced LD formation. VSMCs (8 × 103 cells/coverslip) were incubated with MT-III (0.4 
µM) or DMEM (control) for 1, 3, 6, or 12 h. LDs were quantified using light microscopy after OsO4 
staining. (C) Osmium-stained LDs observed in control or MT-III (0.4 µM) stimulated cells for 1 or 12 
h. Each bar represents the mean ± SEM of the number of LDs/cell in 50 cells. Values represent mean 
± SEM for six animals (n = 6) (ANOVA).Note: * p < 0.05 compared with vehicle treated cells. 
2.2. PLIN2 and PLIN3 Co-Localize with LDs in MT-III-Stimulated VSMCs 
To better understand the stimulatory effect of MT-III on VSMCs leading to LD formation, cells 
exposed to MT-III were immunostained with specific antibodies that recognize either the scaffold 
proteins for LD assembly PLIN2 or PLIN3 and counterstained for neutral lipids of the LD core 
using Nile red. As illustrated in Figure 2a,b, VSMCs stimulated with MT-III (0.4 µM) for 6 h 
exhibited strong fluorescent staining (green) for PLIN2 and PLIN3, with a punctate cytoplasmic 
pattern that was absent in the non-stimulated control cells. Fluorescent Nile Red-labelled LDs were 
virtually absent in non-stimulated control VSMCs. In VSMCs incubated with MT-III, cytoplasmic-
stained PLIN2 and PLIN3 co-localized with Nile red-labelled neutral lipid inclusions. No significant 
staining was detected in control VSMCs. In a further set of experiments, we investigated whether 
Figure 1. MT-III induces LD formation in VSMCs. (A) Effect of MT-III on LD formation in VSMCs
st mulated with selected concentrations of MT-III or with DMEM (control) for 1 h. (B) T me-course of
MT-III-induced LD formati . VSMCs (8 × 103 cells/coverslip) were incubated with MT-III (0.4 µM) or
DMEM (co trol) for 1, 3, 6, or 12 h. LDs were quantified using light micros opy after OsO4 staining.
(C) Osmium-stained LDs observed in control or MT-III (0.4 µM) stimulated cells for 1 or 12 h. Each bar
represents the mean ± SEM of the number of LDs/cell in 50 cells. Values represent mean ± SEM for six
animals (n = 6) (ANOVA).Note: * p < 0.05 compared with vehicl treated cells.
2.2. PLIN2 and PLIN3 Co-Localize with LDs in MT-III-Stimulated VSMCs
To better understand the stimulatory effect of MT-III on VSMCs leading to LD formation, cells
exposed to MT-III were immunostained with specific antibodies that recognize either the scaffold
proteins for LD assembly PLIN2 or PLIN3 and counterstained for neutral lipids of the LD core using
Nile red. As illustrated in Figure 2a,b, VSMCs stimulated with MT-III (0.4 µM) for 6 h exhibited
strong fluorescent staining (green) for PLIN2 and PLIN3, with a punctate cytoplasmic pattern that was
absent in the non-stimulated control cells. Fluorescent Nile Red-labelled LDs were virtually absent in
non-stimulated control VSMCs. In VSMCs incubated with MT-III, cytoplasmic-stained PLIN2 and
PLIN3 co-localized with Nile red-labelled neutral lipid inclusions. No significant staining was detected
in control VSMCs. In a further set of experiments, we investigated whether MT-III would induce the
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protein expression of these LD structural proteins. Western blotting analysis revealed no changes in
the levels of PLIN2 and PLIN3 protein expression in the extracts of cells stimulated with MT-III at
any of the incubation times tested (Figure 3a,b). Altogether, these data reveal that MT-III is able to
induce the recruitment of PLIN2 and PLIN3 from their constitutive sites and confirm the role of these
LD scaffold proteins upon stimulation by the sPLA2 MT-III.
Molecules 2019, 24, x FOR PEER REVIEW 4 of 20 
 
MT-III would induce the protein expression of these LD structural proteins. Western blotting 
analysis revealed no changes in the levels of PLIN2 and PLIN3 protein expression in the extracts of 
cells stimulated with MT-III at any of the incubation times tested (Figure 3a,b). Altogether, these 
data reveal that MT-III is able to induce the recruitment of PLIN2 and PLIN3 from their constitutive 
sites and confirm the role of these LD scaffold proteins upon stimulation by the sPLA2 MT-III. 
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Figure 2. MT-III induces PLIN2 and PLIN3 recruitment to LDs in VSMCs. VSMCs (8× 103 cells/coverslip)
were incubated with DMEM (control) or MT-III (0.4 µM) for 12 h and labelled for LDs (with Nile red)
and for PLIN2 (A) or PLIN3 (B) (with fluorescein isothiocyanate- FITC-conjugated secondary antibody).
The merged image shows co-localization of PLIN2 and PLIN3 to LDs. The pictures are representative
of three independent experiments (n = 9).
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Figure 3. MT-III does not affect PLIN2 or PLIN3 protein expression in VSMCs. VSMCs (5 × 104 
cells/well) were incubated with DMEM (control) or MT-III (0.4 µM) for 1, 3, 6, and 12 h. Western 
blot analysis of PLIN2 (A) and PLIN3 (B) and β-actin (loading control) of the VSMC extracts and the 
densitometric analysis (in arbitrary units - A.U.) of PLIN2 and PLIN3 expression normalized to β-
actin. The results are expressed as the mean ± SEM for three independent experiments (n = 9) 
(ANOVA). 
2.3. Acyl CoA: Diacylglycerolacyltransferase (DGAT) and Acyl-CoA:Cholesterolacyltransferase (ACAT) 
Contribute to LD Formation Induced by MT-III 
Neutral lipids are synthesized locally at LDs during lipid loading [20,21]. As demonstrated in 
Figure 4, the pre-treatment of cells with A922500, a DGAT inhibitor, abolished MT-III-dependent 
LD formation. Additionally, the treatment of cells with TMP-153, an ACAT inhibitor, caused a 
reduction of 77.6% in the number of LDs in MT-III-stimulated VSMCs compared with vehicle-
treated cells stimulated with MT-III. Altogether, these findings show that enzymes involved in the 
synthesis of neutral lipids, such as triacylglycerol and cholesterol, are implicated in LD formation 
induced by MT-III.  
 
Figure 4. Effect of DGAT and ACAT inhibitors on LD formation induced by MT-III. VSMCs (5 × 103 
cells/well) were incubated with A922500 (100 nM) or TMP-153 (100 nM) or vehicle (< 1% DMSO or 
RPMI) for 1 h and then with MT-III (0.4 µM) for 12 h. LDs were quantified using light microscopy 
Figure 3. MT-III does not affect PLIN2 or PLIN3 protein expression in VSMCs. VSMCs (5 × 104 cells/well)
were incubated with DMEM (control) or MT-III (0.4 µM) for 1, 3, 6, and 12 h. Western blot analysis of
PLIN2 (A) and PLIN3 (B) and β-actin (loading control) of the VSMC extracts and the densitometric
analysis (in arbitrary units - A.U.) of PLIN2 and PLIN3 expression normalized to β-actin. The results
are expressed as the mean ± SEM for three independent experiments (n = 9) (ANOVA).
2.3. Acyl CoA: Diacylglycerolacyltransferase (DGAT) and Acyl-CoA:Cholesterolacyltransferase (ACAT)
Contribute to LD Formation Induced by MT-III
Neutral lipids are synthesized locally at LDs during lipid loading [20,21]. As demonstrated in
Figure 4, the pre-treatment of cells with A922500, a DGAT inhibitor, abolished MT-III-dependent LD
formation. Additionally, the treatment of cells with TMP-153, an ACAT inhibitor, caused a reduction
of 77.6% in the number of LDs in MT-III-stimulated VSMCs compared with vehicle-treated cells
stimulated with MT-III. Altogether, these findings show that enzymes involved in the synthesis of
neutral lipids, such as triacylglycerol and cholesterol, are implicated in LD formation induced by MT-III.
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Figure 4. Effect of DGAT and ACAT inhibitors on LD formation induced by MT-III. VSMCs
(5 × 103 cells/well) were incubated with A922500 (100 nM) or TMP-153 (100 nM) or vehicle (< 1% DMSO
or RPMI) for 1 h and then with MT-III (0.4 µM) for 12 h. LDs were quantified using light microscopy after
osmium staining. Each bar represents the mean ± SEM LDs/cell in 50 counted cells. Values represent
means ± SEM from three independent experiments (n = 9) (ANOVA). Note: * p < 0.05 compared with
vehicle treated cells; # p < 0.05 compared with vehicle treated cells stimulated with MT-III.
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2.4. MT-III Induces Increased Protein Expression of ABC Lipid Transporters
ATP-binding cassette transporters ABCA1 and ABCG1 play a major role in cholesterol eﬄux
of macrophage-derived foam cells [22]. As demonstrated in Figure 5a, MT-III induced a significant
increase in ABCA1 protein expression at 3 and 12 h after stimulation with MT-III in comparison with
control cells. In addition, increased expression of ABCG1 was also observed after 3 h of stimulation
with MT-III returning to the basal levels after this time of incubation (Figure 5b). These data indicate
that MT-III upregulates ABCA1 and ABCG1 in VSMC.
Molecules 2019, 24, x FOR PEER REVIEW 6 of 20 
 
after osmium staining. Each bar represents the mean ± SEM LDs/cell in 50 counted cells. Values 
represent means ± SEM from three independent experiments (n = 9) (ANOVA). Note: * p < 0.05 
compared with vehicle treated cells; # p < 0.05 compared with vehicle treated cells stimulated with 
MT-III. 
2.4. MT-III Induces Increased Protein Expression of ABC Lipid Transporters  
ATP-binding cassette transporters ABCA1 and ABCG1 play a major role in cholesterol efflux of 
macrophage- erived foam cell  [22]. As demonstrated in Figure 5a, MT-III induced a significant 
incre se in ABCA1 protein expression at 3 and 12 h after stim lation with MT-III in comparison 
with control cells. In addition, incre sed expression of ABCG1 was also observed after 3 h of 
stimulation with MT-III retu ning to the basal levels after thi  time of incubation (Figure 5b). These 
da a indicate that MT-III upregulat s ABCA1 and ABCG1 in VSMC. 
 
Figure 5. ABCA1 and ABCG1 are upregulated in VSMCs incubated with MT-III. VSMCs (5 × 104 
cells/well) were incubated with MT-III (0.4 µM) or DMEM (control) for 1, 3, 6, and 12 h. (A) Western 
blotting and densitometric analysis of ABCA1 (A) and ABCG1 (B) and β-actin (loading control) in 
VSMC extracts. The densities were normalized with those of β-actin. The results are expressed as 
the mean ± SEM from three experiments (n = 9) (ANOVA). Note: * p< 0.05 compared with control 
cells. 
2.5. MT-III Induces Protein Expression and Translocation of PPAR-γ and PPAR-δ/β in VSMCs 
Considering the ability of PPAR receptors to regulate genes involved in lipid homeostasis and 
inflammation [23], we investigated whether MT-III would induce the protein expression and 
translocation of these transcription factors in VSMCs. Western blotting analysis revealed the 
increased expression of PPAR-γ at 3 and 6 h and PPAR-β/δ at 1 and 3 h after incubation with MT-III 
(Figure 6a,b). In control cells, these receptors were expressed on a basal level. To confirm the 
translocation of these factors after MT-III stimulation in VSMCs, an immunofluorescence staining 
was performed. As illustrated in Figure 6c, immunofluorescence microscopy revealed that VSMCs 
stimulated with DMEM (control) for 6 h exhibited fluorescent staining (green) for PPAR-γ, which 
did not co-localize to nucleus staining (red). However, in VSMCs stimulated with MT-III (0.4 µM) 
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Figure 5. ABCA1 and ABCG1 are upregulated in VSMCs incubated with MT-III. VSMCs (5 × 104 cells/well)
were incubated with MT-III (0.4 µM) or DMEM (control) for 1, 3, 6, an 12 h. (A) Western blotting and
densitometric analysis of ABCA1 (A) and ABCG1 (B) and β-actin (loading control) in VSMC extracts.
The densities were normalized with those of β-actin. The results are expressed as the mean ± SEM
from three experim nts (n = 9) (ANOVA). Note: * p < 0.05 compared with control cells.
2.5. MT-III Induces Protein Expression and Translocation of PPAR-γ and PPAR-δ/β in VSMCs
Considering the ability of PPAR receptors to regulate genes involved in lipid homeostasis
and inflammation [23], we investigated whether MT-III would induce the protein expression and
translocation of these transcription factors in VSMCs. Western blotting analysis revealed the increased
expression of PPAR-γ at 3 and 6 h and PPAR-β/δ at 1 and 3 h after incubation with MT-III (Figure 6a,b).
In control cells, these receptors were expressed on a basal level. To confirm the translocation of
these factors after MT-III stimulation in VSMCs, an immunofluorescence staining was performed.
As illustrated in Figure 6c, immunofluorescence microscopy revealed that VSMCs stimulated with
DMEM (control) for 6 h exhibited fluorescent staining (green) for PPAR-γ, which did not co-localize
to nucleus staining (red). However, in VSMCs stimulated with MT-III (0.4 µM) for 6 h, fluorescent
labeling for PPAR-γ was shown to be co-localized to the nucleus, indicating translocation of this
factor into the nucleus as a result of MT-III stimulation. Similarly, when VSMCs were incubated
with MT-III (0.4 µM) for 1 h and stained for PPAR-β/δ, an identical localization in the nucleus was
observed. To verify the importance of PPARs in MT-III-induced LD formation, cells were pre-treated
ith GSK0660, a PPAR-β/δ inhibitor, and with GW9660, a PPAR-γ inhibitor. As shown in Figure 6d,
pre-treatment of cells with either PPAR-β/δ or PPAR-γ inhibitor abolished LD formation induced by
MT-III. These data reinforce the relevant role of PPARs in the LD formation induced by MT-III.
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Figure 6. MT-III induces activation and upregulation of PPAR-γ and PPAR-δ/β expression in VSMCs.
VSMCs (5 × 104 cells/well) were stimulated with MT-III (0.4µM) or DMEM (control) for 1, 3, 6, and
12 h. (A,B) Western blotting and densitometric analysis of PPAR-γ or PPAR-δ/β and β-actin (loading
control) in VSMC extracts. The densities were normalized with those of β-actin. (C) VSMCs (8 × 103
cells/coverslip) incubated with DMEM (control) or MT-III (0.4 µM) for 1 or 3 h were labeled with
anti-PPAR-γ or -δ/β and visualized with a secondary antibody conjugated to Alexa48 (green).
The nucleus was stained with iodide propidium. The pictures prove an activ tion and translocation
of the PPARs to the nucleus. Shown pictures are representative of three independent experiments.
(D) VSMCs (8 × 103 cells/coverslip) were incubated with GW9662 or GSK0660 (10 µM) PPAR inhibitors
for 1 h and then stimulated with MT-III (0.4 µM) for 12 h. LDs were quantified using light microscopy
subsequent to osmium staining. Each bar represents the mean ± SEM LDs/cell in 50 counted cells from
three independent experiments (n = 9) (ANOVA). Note: * p < 0.05 compared with vehicle treated cells;
# p < 0.05 compared with vehicle treated cells incubated with MT-III.
2.6. MT-III Upregulates SR-A1 and LOX-1 But Not CD36 Protein Expression. None of These Receptors Are
Involved in Lipid Accumulation Induced by MT-III
Foam cell formation, in general, is related to the activation of scavenger receptors, such as CD36,
SR-A1, and LOX-1. As demonstrated in Figure 7a, MT-III did not affect the CD36 protein content, but it
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induced a significant increase in SR-A1 protein expression at 12 h after stimulation in comparison with
control cells (Figure 7b). In addition, MT-III caused a significant increase in LOX-1 protein expression
after 3 and 6 h of stimulation. CD36, SR-A1, and LOX-1 were minimally expressed or absent in control
non-stimulated VSMCs (Figure 7a–c). To verify the participation of these receptors in the MT-III
induced LD accumulation, VSMCs were incubated with compound sulfo-N-succinimidyl oleate (SSO),
an inhibitor of CD36, kappa-carrageenan, a ligand of LOX-1, or fucoidin or dextran sulphate sodium
salts, ligands of SR-A1. As demonstrated in Figure 7d, none of the inhibitors reduced the number
of LDs in MT-III-stimulated VSMCs compared with vehicle-treated VSMCs stimulated with MT-III,
demonstrating that MT-III induced LD accumulation is independent of scavenger receptor function.
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 Figure 7. Effect of MT-III on protein expression of SR-A1, LOX-1, and CD36 by VSMCs and the
effect of scavenger receptor inhibitors on LD formation induced by MT-III. VSMCs (5 × 104 cells/well)
were incubated with MT-III (0.4 µM) or DMEM (control) for 1, 3, 6, and 12 h. Western blotting and
densitometric analysis of CD36 (A), SR-A1 (B), LOX-1 (C), andβ-actin (loading control) in VSMC extracts.
The densities were normalized with those of β-actin. (D) Treatment of VSMCs (8 × 103 cells/coverslip)
with SSO (250µM) or fucoidin, dextran sulphate sodium salt (250 µM), or kappa-carrageenan (250 µM)
for 1 h before stimulation with MT-III (0.4µM) for 12 h. LDs were counted using light microscopy after
osmium staining. The results are expressed as the mean ± SEM from three independent experiments
(n = 9) (ANOVA). Note: * p < 0.05 compared with control cells.
2.7. MT-III Increases acLDL Uptake by VSMCs
The role of SR-A1 and LOX-1 receptors in the uptake of modified lipids has been largely
evidenced [24,25]. On this basis, the ability of MT-III to modulate acLDL uptake in VSMCs was further
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investigated by treating cells with MT-III for 12 h followed by exposure to acLDL (1.5 µg/mL) for 24 h.
As shown in Figure 8a,b, fluorescent acLDL particles were virtually absent in non-stimulated control
VSMCs. After incubation with MT-III (0.4 and 0.8 µM), significant increase in the uptake of Alexa Fluor
488-acLDL by VSMCs was seen in comparison with control cells. These data reveal that MT-III exerts
stimulatory effects on SR-A-1-mediated acLDL uptake activities. Moreover, despite the reported low
affinity of LOX-1 receptor to acLDL uptake [26], the contribution of this receptor to the effect triggered
by MT-III cannot be ruled out.Molecules 2019, 24, x FOR PEER REVIEW 10 of 20 
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Figure 8. Effect of MT-III on acLDL uptake by VSMCs. (A) The first column illustrates the result image
from the high content analysis made with the CellProfiler (scale bar 250 µM). The second column
illustrates the single channel of the incorporated AlexFluor488 labeled acLDL. The third column shows
a magnified view of the result image (Scale bar 25 µM). (B) Quantification of the number of Alexa
Fluor 488-acLDL particles captured by VSMCs upon stimulation by the sPLA2 MT-III. The results are
expressed as the mean ± SEM from two independent experiments (n = 6) (ANOVA). Note: * p < 0.05
compared with control cells.
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2.8. Macropinocytosis But Not Receptor-Mediated Endocytosis is Involved in MT-III-Induced LDs Formation
To verify the role of endocytosis in MT-III-induced LD formation, VSMCs were pre-treated with
dynasore (100 µM), an inhibitor of dynamin cytoskeleton protein known to block receptor-mediated
endocytosis, or its vehicle (control) before incubation with MT-III (0.4µM), followed by the quantification
of osmium-stained LDs. As demonstrated in Figure 9a, dynasore did not change the number of LDs
in MT-III-stimulated VSMCs compared with vehicle-treated VSMCs. Recently, many studies have
demonstrated that lipid uptake by VSMCs also occurs through the macropinocytosis process, which
is dependent on PI3K [27,28]. In this sense, PI3K inhibitors are considered classical inhibitors of
this process. To verify the role of macropinocytosis in MT-III induced LD formation, VSMCs were
pre-treated with inhibitors of PI3K, wortmaninn (2 µM), or LY294002 compound (100 µM) or their
vehicles for 1 h. Next, cells were incubated with MT-III (0.4 µM) or DMEM for 12 h. As shown in
Figure 9b, treatment of VSMCs with either wortmaninn or LY294002 caused a significant reduction in
the number of LDs in MT-III-stimulated VSMCs compared with vehicle-treated and MT-III-stimulated
cells (70 and 60.8%, respectively). These findings indicate that macropinocytosis is implicated in LD
formation induced by MT-III.
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genes (smooth muscle alpha actin, SM22 alpha, and MHY11), driving them into a phenotype that is 
positive for macrophage markers (CD163, CD68, and MAC2). For this purpose, VSMCs were 
incubated with MT-III for 48 h and processed for gene expression analysis. Figure 10c demonstrates 
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Figure 9. Effect of inhibitors of macropinocytosis and receptor-mediated endocytosis in MT-III-induced
LD formation in VSMCs. VSMCs (8 × 103 cells/coverslip) were incubated with one of the following
inhibitors before stimulation with MT-III (0.4 µM) for 12 h: (A) dynasore (100 µM) for 1 h or (B)
LY294002 (100 µM) or wortmaninn (2 µM) for 1 h. LDs were counted using light microscopy after
osmium staining. Each bar represents the mean ± SEM of the number of LDs/cell in 50 cells. Values
represent means ± SEM for three independent experiments (n = 9) (ANOVA). Note: * p < 0.05 compared
with vehicle treated cells; # p < 0.05 compared with vehicle treated cells incubated with MT-III.
2.9. MT-III Increases VSMC Phagocytic Activity a Upregulates Macrophage-Related Genes
To investigate whether MT-III would also induce VSMCs to acquire functional aspects of
macrophages, such as phagocytosis, VSMCs were incubated with MT-III (0.4 or 0.8 µM) for 12,
24, or 48 h followed by incubation with 0.5-µm fluorescent beads for 6 h. As shown in Figure 10a,
control VSMCs presented low phagocytotic activity (1 bead/cell). After incubation with MT-III (0.4
and 0.8 µM) for 48 h, the accumulation of latex beads per cell significantly increased (489 and 613%,
respectively) in comparison with controls. No significant changes in the phagocytic activity of VSMCs
were seen at 12 or 24 h of incubation. Figure 10b shows VSMCs incubated with MT-III for 48 h.
In control cells, a negligible number of beads per cell was seen. However, the incubation of VSMCs
with MT-III for 48 h led to increased phagocytic activity and consequently an accumulation of beads in
these cells. The ability of VSMCs to sustain phenotypic modulation is a result of changes in VSMC gene
expression [29]. Therefore, we evaluated if MT-III would modulate the rat VSMC genes (smooth muscle
alpha actin, SM22 alpha, and MHY11), driving them into a phenotype that is positive for macrophage
markers (CD163, CD68, and MAC2). For this purpose, VSMCs were incubated with MT-III for 48 h and
processed for gene expression analysis. Figure 10c demonstrates that the incubation of VSMCs with
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MT-III at concentrations of 0.4 and 0.8 µM induced an increased expression of the typical macrophage
genes CD68 and MAC2, which was significantly different from control cells (223%, 92% and 274%,
273%, respectively). No alteration was seen in the gene expression of the VSMC markers alpha actin,
SM22α, or MYH1 during the analyzed period. These findings demonstrate that MT-III-stimulated
VSMCs acquire the macrophage phenotype with phagocytic activity.
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Figure 10. Phagocytotic activity and upregulation of macrophage markers in VSMCs induced by MT-III.
VSMCs (2.5 × 103 cells/well) were treated with MT-III (0.4 and 0.8 µM) or DMEM (Control) for 12, 24,
and 48 h, followed by incubation with 0.5 µm fluorescent beads (red) for 6 h. Cells were then washed
extensively, fixed with paraformaldehyde (4%), counterstained with Hoechst 33342 (blue-nuclei), and
analyzed with an automated Axiovert 200 m followed by a computerized automatic quantification
in the CellProfiler analysis software. (A) The number of latex beads per cell was counted to obtain
numerical data for the total phagocytotic activity. (B) A representative field of view. (C) The effect of
MT-III on VSMC and macrophage-related gene expression in rat VSMCs. Subconfluent rat VSMCs
(8 × 105 cells/well) were treated with MT-III (0.4 and 0.8 µM) or with DMEM medium (control) for 48 h.
Total RNA was extracted and subjected to RT-PCR analysis. Values represent the mean ± SEM from six
animals (n = 6) (ANOVA). Note: * p < 0.05 compared with control cells.
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3. Discussion
In this study, we present data demonstrating, for the first time, the ability of MT-III, a GIIA sPLA2,
to induce the formation of LDs in VSMCs and dissect the lipid metabolism factors involved in this effect.
In addition, the ability of sPLA2s to induce VSMC phenotypic switch to macrophage-like cells is also
reported, to the best of our knowledge for the first time. Our results also show that the MT-III-induced
formation of lipid droplets in VSMCs is a concentration- and time-dependent effect. The ability of
GIIA and GX sPLA2s to induce the formation of LDs and macrophage-derived foam cells has been
previously demonstrated [13,30,31].
PLIN2 and PLIN3 are considered scaffold proteins for LD formation. During lipid loading, PLIN2
is mobilized from the cell membrane to the cytoplasm and contributes to long-chain fatty acid capture
and LD formation [32]. PLIN3—which is constitutively found in the cytoplasm of cells—acts in the
same way, contributing to LD formation and foam cell formation [33]. In this context, our findings,
demonstrating that MT-III recruits PLIN2 and PLIN3 from their constitutive storages, imply the
importance of both proteins for the LD assembly in VSMCs.
Triacylglycerol (TG) and cholesterol (CE) are major components of LDs and are synthesized by
DGAT and ACAT enzymes, which are located in the endoplasmic reticulum [23,24]. The contribution
of the ACAT enzyme to VSMC-derived foam cell formation has already been reported in stimulated
mouse VSMCs by cholesterol-cyclodextrin complexes [29]. Our results showing that the inhibition
of both DGAT and ACAT enzymes abolished the LD formation induced by MT-III implicate these
enzymes in the mechanism involved in MT-III-induced LD formation. Their contribution probably
occurs due to their ability to provide TG (triacylglycerol) and cholesteryl esters (CE) to LD assembly.
ABCA1 and ABCG1 are two known common regulators of intracellular fatty acid levels and play
an important role in regulating foam cell formation. The former plays a critical role in the eﬄux of
free cholesterol from cells [25] by removing this lipid from the cell cytoplasm to lipid-poor apoA1
particles, and the latter acts in concert with ABCA1, being responsible for cellular cholesterol eﬄux to
lipidated high-density lipoprotein (HDL) [25,34]. In addition, during pathophysiological conditions
after initial cholesterol loading, VSMCs upregulate ABCA1 and ABCG1 levels. With continued lipid
loading, VSMCs downregulate the levels of the cholesterol transporters, enhancing the formation of
foam cells [35]. In this sense, our results demonstrating increased protein expression of both ABCA1
and ABCG1 upon stimulus by MT-III are in line with the accumulation of high levels of lipids induced
by MT-III, suggesting a mechanism by which VSMCs restore the lipid balance of homeostasis after the
formation of LDs. In line with our hypothesis, the ability of 17β-estradiol to promote cholesterol eﬄux
from VSMCs through a mechanism dependent upon the upregulation of ABCA1 and ABCG1 has been
described [36].
It is known that fatty acid metabolism is regulated by many transcription factors, such as PPARs.
During atherosclerosis, PPARs display dual roles as they can contribute to either progression or
resolution of the inflammatory process and foam cell formation [37]. These transcription factors can
increase lipid uptake by human VSMCs through increased expression of not only PLIN2, but also
by the scavenger receptors SR-A1 and CD36, which are related to fatty acid capture and foam cell
formation [38]. Our results demonstrating that MT-III upregulated PPAR-γ and β/δ protein expression
in VSMCs and that the pharmacological inhibition of both isoforms abolished the LD formation
induced by MT-III indicate the essential role of these receptors in the formation of LDs upon stimulation
by this sPLA2 in VSMCs. In contrast to these findings, although the upregulation of SR-A1 and
LOX-1 expression was found in MT-III-stimulated VSMCs, scavenger receptors, including CD36,
do not play a role in the LD accumulation induced by MT-III, as demonstrated by receptor- specific
pharmacological interventions. In spite of these data, increased expression of LOX-1 and SR-A1
scavenger receptors was translated into a marked uptake of acLDL by VSMCs stimulated with MT-III.
These findings demonstrate for the first time that a GIIA PLA2 is capable of modulating the capture
of modified lipids through increased expression of scavenger receptors, such as SR-A1 and LOX-1.
Considering these results, the increased expression of the eﬄux transporters ABCA1 and ABCG1
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found in MT-III-stimulated cells may be a consequence of the increased uptake of acLD and other fatty
acids to restore lipid balance of MT-III-stimulated cells.
Macropinocytosis is recognized as an alternative pathway by which cells can accumulate lipids,
especially lipids that have undergone minimal or no chemical modifications, and has been described
as an essential process for VSMC-derived foam cell formation [27,28]. Our results provide the first
evidence that macropinocytosis contributes to the LD formation induced by a sPLA2, demonstrating
that the inhibition of PI3K, a signaling protein essential for the macropinocytosis process, results in a
marked reduction of the LD formation induced by MT-III. However, the mechanism by which MT-III
activates PI3K was not investigated. On the other hand, the process of endocytosis mediated by the
receptor is not involved in the LD formation induced by this sPLA2.
Recently, a number of reports have demonstrated that a large proportion of foam cells found in
atherosclerotic lesions are derived from VSMCs rather than monocytes [39]. In addition, the expression
of the macrophage markers, such as CD68, MAC2, and CD163 [29,34], by foam VSMCs and the
presence of cells expressing both VSMCs and macrophage markers has been demonstrated in human
aortic intima preparations [39]. Moreover, VSMCs loaded with lipids have been shown to acquire the
macrophage phenotype, with phagocytic activity and the capability to express macrophage markers.
Our finding that MT-III-stimulated VSMCs were capable of phagocytosis indicate that MT-III induces
a gain of phagocytic activity by VSMCs. This phenomenon was accompanied by the increased
expression of the macrophage markers MAC2 and CD68, providing evidence that MT-III induces the
transdifferentiation of VSMCs into a macrophage-like phenotype. Our data are in agreement with
the existing literature demonstrating that VSMC-derived foam cells are able to perform macrophage
functions [29,40]. Although the mechanisms by which MT-III modulates VSMC plasticity remain to be
clarified, this is to the best of our knowledge the first demonstration of the ability of a sPLA2 to induce
modulation of the VSMC phenotype.
In summary, the data obtained herein allow us to conclude that MT-III induces LD formation in
VSMCs. This phenomenon was shown to be dependent on the enzymes ACAT and DGAT, PPAR-γ
and β/δ, and the macropinocytosis process, but not on the scavenger receptors CD36, SR-A1, or LOX-1.
Furthermore, MT-III is capable of inducing phenotypic modulation in these cells by reprogramming
them at a transcriptional level to a different functional behavior by acquiring macrophage-like
characteristics. Finally, our study provides new insights into the GIIA-secreted phospholipase A2
activities in VSMCs and the role of this class of enzymes in VSMC-derived foam cell formation, as well
as in their phenotypic plasticity.
4. Material and Methods
4.1. Animals
Male Wistar rats (180–220 g) were obtained from the Butantan Institute, São Paulo, Brazil. Animals
were housed in a temperature-controlled room (22–24 ◦C) with a 12 h light–dark cycle and fresh
water and food ad libitum until use. Animals were euthanized after anesthesia by intraperitoneal (ip)
injection of pentobarbital (100 mg/kg). The study was approved by the Butantan Institute Animal
Experimentation Ethics Committee (reference no. 1024/13) and all procedures were in accordance with
the NIH Guideline for the Care and Use of Laboratory Animals (NIH Publication, 8th Edition, 2011).
4.2. Phospholipase A2
Group IIA sPLA2 from B. asper venom, named MT-III (Uniprot accession no: P20474), was purified
by ion-exchange chromatography on CM-Sephadex C-25 using a KCl gradient from 0 to 0.75 M at
pH 7.0, as previously described [41], followed by RP-HPLC on a semi-preparative C8 column (Vydac;
10 × 250 mm, 5 µm particle size) eluted at a flow rate of 2.5 mL/min with a gradient of acetonitrile
(0–70%, containing 0.1% trifluoroacetic acid) over 30 min [42]. Homogeneity was verified by SDS-PAGE
run under reducing conditions, in which a single band of 14 kDa was observed. The complete
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amino acid sequence of this enzyme has been described previously [41]. The absence of endotoxin
contamination in the MT-III batches used was demonstrated by performing a quantitative LAL test,
which revealed undetectable levels of endotoxin (<0.125 EU/mL).
4.3. Cell Isolation and Culture
Rat VSMCs were obtained by spontaneous outgrowth from the thoracic aorta, as described by
Metz el al. [43]. In brief, the thoracic aorta was dissected and transferred to a Petri dish with phosphate
buffered saline (PBS) pH 7.2 supplemented with 40 µg/mL gentamicin sulphate (Thermo Fischer,
Waltham, MA, USA) and 2 mM L-glutamine (Thermo Fischer, Waltham, MA, USA. Connective and
adventitia layers were removed, and aortas were transferred to sterile tubes containing collagenase IV
(Thermo Fischer, Waltham, MA, USA) (1 mg/mL). After 90 min, the aortas were washed with PBS and
the endothelial layer was removed with a sterile cotton swab. Next, the aortas were spread out into
culture plates and low-glucose (LG) DMEM (Thermo Fischer, Waltham, MA, USA) supplemented with
10% fetal bovine serum, 40 µg/mL gentamicin sulphate, and 2 mM L-glutamine was added. Plates
were maintained at 37 ◦C with 5% CO2. Samples were left undisturbed for 7 days. Isolated VSMCs
presented an elongated morphology and stained positively for alpha-actin, a constitutive protein
of this type of cell. In addition, homogeneity of VSMC culture was confirmed by flow cytometry.
These cells were applied in experimental protocols between passages 5 and 8. Each experiment was
performed either twice or three times with three samples (n = 6–9). Each cell sample was obtained
from a single animal.
4.4. Stimulation and Treatment of Vascular Smooth Muscle Cells
VSMCs were plated on glass coverslips in 24-well plates at a density of 8 × 103 cells/coverslip and
allowed to attach at 37 ◦C under a 5% CO2 atmosphere. Serum-starved primary cultured rat VSMCs were
challenged with selected concentrations of MT-III (0.2–0.8 µM, dissolved in LG-DMEM) or LG-DMEM
alone (control). Where appropriate, the following inhibitors were used: 10 µM GW9662 inhibitor of
PPAR-y, 10 µM GSK0660; inhibitor of PPAR-β/δ, 100 nM A922500; inhibitor of DGAT, 100 nM TMP-153;
inhibitor of ACAT (Calbiochem-Novabiochem Corp., La Jolla, CA, USA), 250µM SSO; antagonist of
CD36, 250 µM kappa-carrageenan; antagonist of LOX-1, 250 µM fucoidin and dextran sulphate sodium
salt (DSF); inhibitors of SR-A1, 100µM LY294002, 2µM wortmannin; inhibitors of phosphatidylinositide
3-kinases (PI3K), and inhibitor of endocytosis mediated by receptor, 100 µM dynasore. All stock
solutions were prepared in DMSO and stored at −20 ◦C. Aliquots were diluted in LG-DMEM low
glucose to the required concentration immediately before use. The final DMSO concentration was
always lower than 1% and had no effect on lipid droplet numbers. All pharmacological inhibitors
or < 1% DMSO were added 60 min before the stimulation of VSMCs with MT-III or LG-DMEM
(control). Cells treated with the inhibitors were analyzed for viability by the tetrazolium-based (MTT)
colorimetric assay. No significant changes in cell viability were registered with any of the above agents
or vehicle at the concentrations used.
4.5. Lipid Droplet Staining and Quantification
Analysis of lipid droplet numbers was performed in osmium-stained cells. In brief, VSMCs
(8 × 103 cells) stimulated with MT-III (0.4 µM) or LG-DMEM (control) adhered to glass coverslips
were fixed in 4% paraformaldehyde (PFA) in 0.1 M PBS pH 7.2 for 15 min. The coverslips were then
rinsed in 0.1 M phosphate buffer, stained in 1% OsO4 (30 min), rinsed in deionized H2O, immersed
in 1.0% thiocarbohydrazide (5 min), rinsed again in 0.1 M phosphate buffer, restained with 1% OsO4
(3 min), rinsed with H2O, and then dried and mounted. The morphology of the fixed cells was
observed and round osmiophilic structures were identified as lipid droplets, which were then counted
by phase-contrast microscopy using a 100× objective lens in 50 consecutively acquired VSMCs in
each coverslip.
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4.6. Western Blotting
Whole cell extracts were lysed with 100 µL of sample buffer (0.5 M Tris-HCl, pH 6.8, 20% SDS,
1% glycerol, 1 M β-mercaptoethanol, 0.1% bromophenol blue) and boiled for 10 min. Samples were
resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) on 10% bis-acrylamide gels. Proteins
were then transferred to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK) using a
Mini Trans-Blot® (Bio-Rad Laboratories, Richmond, CA, USA). The membranes were blocked for 1 h
with 5% non-fat dry milk in TTBS (20 mM Tris, 100 mM NaCl, and 0.5% Tween 20) and incubated
with primary antibodies against PLIN2 (Abcam, San Francisco, CA, USA), PLIN3 (Abcam), COX-1
(Merck KGaA, Darmstadt, Germany), COX-2 (Life Technologies Corporation, Carlsbad, CA, USA),
CD36 (R&D Systems, Minneapolis, MN, USA), SR-A1 (Thermo Fisher, Waltham, MA, USA) or PPAR-y
and β/δ (Santa Cruz, Dallas, TX, USA) or LOX-1, ABCA1, or ABCG1 (Abcam) overnight at 4 ◦C or
β-actin (Sigma-Aldrich Corporation, St. Louis, MO, USA) for 1 h at room temperature. They were
then washed and incubated with the appropriate secondary antibodies conjugated to horseradish
peroxidase. Detection was performed by the enhanced chemiluminescence (ECL) method according to
the manufacturer’s instructions (GE Healthcare). Band densities were quantified with ImageQuant
LAS4000 mini (GE Healthcare) mini using the image analysis software from ImageQuant LAS.
4.7. Quantification of Phagocytosis
After treatment with non-cytotoxic concentrations of MT-III, VSMCs were exposed to 0.5 µm
Flouresbrite® fluorescent beads (Polyscience Inc., Warrington, PA, USA) for 12, 24, and 48 h. Next, cells
were washed three times with PBS, and nuclei were stained with Hoechst 33342 fluorescent dye. Data
acquisition was accomplished with automated Axiovert 200m (Carl Zeiss MicroImaging GmbH, Jena,
Germany) followed by a computerized automatic quantification in the CellProfiler analysis software.
4.8. Quantification of acLDL Uptake
Rat VSMCs were seeded with a density of 10,000 cells per cm2 on glass bottom 24-well plates
(Zell-Kontakt GmbH, Nörten-Hardenberg, Germany) and cultured overnight in DMEM low glucose
supplemented with 10% of fetal bovine serum (Gibco/LifeTechnologies/ThermoFisher scientific;
Gibco/Lifetechnologies/ThermoFisher scientific; HyClone SV30079.01 GE). After 24 h, cells were starved
for 48 h in DMEM low glucose and stimulated with MT-III (0.4 or 0.8µM) for 12 h. After stimulation, cells
were washed three times with DMEM low glucose and exposed to 1.5 µg/mL AlexaFluor488-labeled
acLDL (ThermoFisher Scientific) in DMEM low glucose supplemented with 10% of FCS for 24 h.
Cells were then fixed with freshly prepared 3% formaldehyde solution for 10 min. Next, cells were
washed three times to remove non-internalized acLDL and stained with Hoechst 33342 (10 µg/mL
ThermoFisher scientific). After 60 min, the samples were analyzed by automated microscopy using
a Zeiss Axiovert 200m (Carl Zeiss, Jena, Germany) equipped with a motorized stage (Märzhäuser
Wetzlar GmbH and Co. KG, Wetzlar, Germany), Colibri2 (Carl Zeiss, Jena, Germany), and the filter set
62HE. Mosaic images with 6 × 8 single images were acquired with a Neofluar 40x/0.75 representing
1000 × 1000 µm of the sample. The images were stitched and exported as Tiff files. The images were
scaled down to 50%, resulting in 4000 × 4000 pixel images. High-resolution optical section images
of representative areas were created using Apotome2 in conjunction with a Neofluar 40x/1.3 of the
Axiovert 200m. The stacks were processed in ImageJ and are shown as maximum intensity projections.
4.9. Immunocytochemistry Analysis
Detection of PLIN2, PLIN3, and PPAR-γ and β/δ in MT-III-stimulated VSMCs was performed by
immunostaining. Cells were fixed in 2% PFA, permeabilized with 0.2% Triton-X 100 in 0.1 M phosphate
buffer, and blocked with 0.5% albumin in 0.1 M phosphate buffer for 30 min. After PBS washes, VSMCs
were incubated for 1 h with polyclonal antibodies against PLIN2 and PLIN3 (Abcam, CA, USA) or
PPAR-γ and β/δ (1:250) (Santa Cruz, TX, USA) diluted in 0.1 M phosphate buffer with 0.2% Triton-X 100.
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After three washes with PBS, the preparations were incubated with secondary Alexa488-conjugated
antibody (1:500) (Thermo Fisher, Waltham, MA, USA) for 1 h. After the washes, the slides were
mounted with Fluoromount-G and examined under a confocal laser scanning microscope (Zeiss LSM
510 Meta).
4.10. Real-Time PCR
To explore the transcriptional changes of the VSMC after MT-III treatment, VSMCs were incubated
with LG-DMEM (control) or MT-III (0.4 or 0.8 µM) and lysed with lysis buffer. Total RNA was isolated
using the InviTrap® Spin Cell RNA Mini Kit (STRATEC Molecular GmbH). The cDNA was synthesized
with the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific Inc., Waltham, MA,
USA) from 1 mg total RNA using random hexamer priming. Real-time PCR was performed to detect
the relative expression levels of genes known to describe the phenotypic shift, such as MAC-2, CD68,
and CD163 (to characterize macrophage-like phenotype), as well as smooth muscle actin, SM22, and
myosin heavy chain (to characterize VSMCs)44 normalized to HPRT-1 using the CFX96 real-time PCR
System (Bio-Rad Laboratories) and SYBR Premix ExTaq™ (Lonza Group Ltd., Basel, Switzerland).
4.11. Statistical Analysis
Data are expressed as the mean ± standard error of the mean (SEM) of at least three independent
experiments. Multiple comparisons among groups were performed by one-way analysis of
variance (ANOVA) followed by Tukey’s test. Values of probability lower than 5% (p < 0.05) were
considered significant.
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